Coloplast A/S (OTCMKTS:CLPBY) Short Interest Update

Coloplast A/S (OTCMKTS:CLPBY) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 280,600 shares, an increase of 264.4% from the February 28th total of 77,000 shares. Based on an average daily volume of 482,700 shares, the days-to-cover ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CLPBY shares. Sanford C. Bernstein upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th. Royal Bank of Canada upgraded shares of Coloplast A/S from a “hold” rating to a “moderate buy” rating in a report on Monday, March 3rd. Finally, UBS Group upgraded shares of Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th.

Coloplast A/S Price Performance

CLPBY stock traded up $0.02 during mid-day trading on Friday, reaching $10.52. The company had a trading volume of 94,249 shares, compared to its average volume of 200,453. The firm has a fifty day simple moving average of $11.00 and a 200 day simple moving average of $11.92. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.02 and a quick ratio of 0.66. Coloplast A/S has a fifty-two week low of $10.31 and a fifty-two week high of $14.14.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings data on Tuesday, February 4th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. Sell-side analysts forecast that Coloplast A/S will post 0.31 EPS for the current fiscal year.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.